Cybin

​Cybin is a clinical-stage biopharmaceutical company dedicated to developing psychedelic-based therapeutics to address mental health conditions. Founded in 2019 and headquartered in Toronto, Canada, Cybin focuses on creating proprietary drug discovery platforms and innovative drug delivery systems. Their lead programs include CYB003, a deuterated psilocin analog in Phase 3 trials for major depressive disorder, and CYB004, a deuterated dimethyltryptamine (DMT) molecule in Phase 2 studies for generalized anxiety disorder. Cybin's efforts aim to provide new treatment options for individuals suffering from mental health disorders.